A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?

Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic...

Full description

Saved in:
Bibliographic Details
Published inCardiology and therapy Vol. 7; no. 1; pp. 25 - 44
Main Authors Szekely, Yishay, Arbel, Yaron
Format Journal Article
LanguageEnglish
Published Cheshire Springer Healthcare 01.06.2018
Springer Nature B.V
Subjects
Cardiology
Cytokines
Internal Medicine
Medicine
Medicine & Public Health
Monoclonal antibodies
Review
Sepsis
Heart failure
Myocardial infarction
Myocarditis
Pericarditis
Interleukin-1
Arrhythmia
Sepsis-induced cardiomyopathy
Canakinumab
Anakinra
Online AccessGet full text

Cover

More Information
Summary:Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic target in various inflammatory states. Recent trials have explored the effect of Interleukin-1 blockade in cardiovascular diseases and initial evidence of the relevance of such treatment in this field of medicine accumulate. This review will describe the role of Interleukin-1 in heart diseases and the potential therapeutic effect of its blockade in such diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ISSN:2193-8261
2193-6544
DOI:10.1007/s40119-018-0104-3